4 news items
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
NMRA
14 May 24
receptor (KOR) antagonist, a novel mechanism of action in development for the treatment of major depressive disorder (MDD) and bipolar depression
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
ADIL
AEYE
ATHE
15 Apr 24
announced that it sold its majority interest in Utah Hospitals.
CareMax, Inc
Why Is Neurology Focused-Neumora Therapeutics Shares Trading Lower On Monday?
NMRA
15 Apr 24
, Neumora…We anticipate several important milestones, including Phase 3 data in major depressive disorder and the initiation of a Phase 2 study
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
NMRA
15 Apr 24
data in major depressive disorder and the initiation of a Phase 2 study in bipolar depression with navacaprant, our kappa opioid receptor antagonist
- Prev
- 1
- Next